U.S., June 5 -- ClinicalTrials.gov registry received information related to the study (NCT07003997) titled 'JAK Signaling in Depression' on May 26.
Brief Summary: This study will test the hypothesis that Janus kinase (JAK) signaling is involved in major depression (MD) with high inflammation by determining whether its inhibition with baricitinib can improve functional connectivity in reward and motor circuits in association with improved motivation and motor function in MD patients enriched for high C-reactive protein (CRP) and anhedonia.
Study Start Date: June, 2025
Study Type: INTERVENTIONAL
Condition:
Major Depressive Disorder
Intervention:
DRUG: Baricitinib
This small molecule, orally bioavailable agent is an immunosuppressant (...